Ticker | Value | Shares | Price | Security | Type | Insider | Title | Return | Flags | Date |
|---|---|---|---|---|---|---|---|---|---|---|
| No transactions found | ||||||||||
Avenue Capital Boston currently holds 356,824 shares of EDEN BIOSCIENCE CORP (EDEN), valued at approximately $0. This represents their equity stake as Executive.
Based on SEC Form 4 filings, Avenue Capital Boston has been a net seller of EDEN stock. They have purchased $2.1M and sold $2.6M worth of shares.
Avenue Capital Boston's most recent insider trade was on May 28, 2009, when they purchased 111 shares at $1.32 per share.
Avenue Capital Boston serves as Executive at EDEN BIOSCIENCE CORP (EDEN). They have executed 57 insider transactions totaling $4.7M over their tenure at the company.
Avenue Capital Boston holds the position of Executive at EDEN BIOSCIENCE CORP, where they are responsible for executive-level decision-making and strategic oversight. They have been associated with the company for 20 years and currently hold a stake valued at $0.
Avenue Capital Boston has shown a selling trading pattern, with $2.1M in total purchases and $2.6M in total sales across all transactions. Their most recent activity indicates a tendency to reduce their position.
The largest transaction by Avenue Capital Boston was on Feb 20, 2007, when they sold $1.1M worth of MALL shares. This transaction involved 83,895 shares at $13.69 per share.
Avenue Capital Boston currently owns 356,824 shares of EDEN BIOSCIENCE CORP (EDEN), with an estimated value of $0. This stake represents their equity holdings accumulated through purchases, awards, and option exercises.
All of Avenue Capital Boston's SEC Form 4 insider trading filings are tracked on this page. Each transaction links directly to the official SEC EDGAR filing. Avenue Capital Boston has 57 Form 4 filings on record as an insider at EDEN BIOSCIENCE CORP.
Set alerts for Avenue Capital Boston and 40,000+ other insiders.